Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Golidocitinib by Dizal Pharmaceutical for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Golidocitinib is under clinical development by Dizal Pharmaceutical and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...
Golidocitinib by Dizal Pharmaceutical for Sezary Syndrome: Likelihood of Approval
Golidocitinib is under clinical development by Dizal Pharmaceutical and currently in Phase II for Sezary Syndrome. According to GlobalData, Phase...
Golidocitinib by Dizal Pharmaceutical for Cutaneous T-Cell Lymphoma: Likelihood of Approval
Golidocitinib is under clinical development by Dizal Pharmaceutical and currently in Phase II for Cutaneous T-Cell Lymphoma. According to GlobalData,...